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Sex-specific associations between cortisol and birth
weight in pregnancies complicated by asthma are not
due to differential glucocorticoid receptor expression
Nicolette A Hodyl,1 Hayley Wyper,2 Annette Osei-Kumah,1 Naomi Scott,2
Vanessa E Murphy,3 Peter Gibson,3 Roger Smith,2 Vicki L Clifton1
ABSTRACT
Background Fetal growth inhibition is a known sequelae
of in utero glucocorticoid exposure and has long-term
consequences for adult health. Sex-specific fetal growth
patterns are observed in pregnancies with maternal
asthma and may be due to differential sensitivity of the
placenta to glucocorticoids. It is currently unknown
whether expression of the placental glucocorticoid
receptor (GR) becomes altered with asthma or the use of
inhaled corticosteroids.
Methods Pregnant women with mild asthma (n¼52),
moderateesevere asthma (n¼71) and without asthma
(n¼51) were recruited at John Hunter Hospital,
Newcastle, Australia. At delivery, placentae and cord
blood were collected, and fetal sex and birth weight
were recorded. Placental GR heterogeneous nuclear RNA
(hnRNA), mRNA and protein were measured and cord
blood cortisol concentrations were assessed.
Results Placental GR gene activity increased with
cortisol exposure but decreased with inhaled
corticosteroid treatment (p¼0.05). With maternal
asthma, female birth weight centiles were inversely
associated with cortisol (r¼0.286, p¼0.017) and,
despite a decrease in placental GR mRNA (p¼0.003),
placental GRa protein levels were unchanged. In males,
no change to cortisol, birth weight or placental GR were
evident in pregnancies with asthma. Together, these
results indicate that in pregnancies complicated by
asthma, placental GR gene activity, but not mRNA
expression or protein levels, is dependent on cortisol and
inhaled corticosteroid treatment.
Conclusions The sex-specific associations between
cortisol and birth weight observed in pregnancies with
asthma are not due to altered GR expression; however,
they may be due to differential glucocorticoid sensitivity
via preferential transcription of GR isoforms or post-
translational modifications.
INTRODUCTION
With the increasing prevalence of childhood allergy
and atopic disease worldwide, an urgent need has
arisen to understand in utero mechanisms that
predispose infants towards this outcome. These
mechanisms are currently unknown; however, the
contribution of maternal asthma and atopy during
pregnancy to wheeze and atopic symptoms in
childhood is in the preliminary stages of investiga-
tion.1 2 Retrospective studies have indicated that
maternal atopy alters feto-placental immune
mechanisms, with cord blood cytokine concentra-
tions skewed towards a type 2 T helper proﬁle.3e5
Ongoing work from our laboratory has
demonstrated that the effects of maternal asthma
during pregnancy on feto-placental immunity are
dependent on asthma severity and use of inhaled
corticosteroids (ICS) for asthma treatment, and
differ according to fetal sex.6e9 Further, maternal
asthma is associated with a reduction in female
birth weight,9 and low birth weight has been
independently linked to other adverse health
outcomes in both children and adults.10
Animal and human studies indicate that fetal
growth is reduced following excess exposure to
glucocorticoids (for a review, see Seckl and
Holmes11). This appears to be an important factor
driving the sex-speciﬁc reduction in birth weight
that we have previously reported in pregnancies
complicated by asthma. Speciﬁcally, an asthma-
induced reduction in the placental cortisol-metab-
olising enzyme, 11b hydroxysteroid dehydrogenase
type 2 (11b-HSD2) was associated with reduced
female birth weights.9 This reduction in 11b-HSD2
activity increases exposure of the female fetus to
cortisol. In these studies, the use of ICS to manage
asthma restored female birth weight centiles to
control levels and normalised 11b-HSD2 activity.12
The protective effect on female birth weight
conferred by ICS treatment for maternal asthma
may be due to sexually dimorphic alterations in
placental glucocorticoid responsiveness.
Responsiveness to glucocorticoids is mediated
both centrally and peripherally by the glucocorticoid
receptor (GR), of which there are multiple
isoforms.13 We have previously identiﬁed the pres-
ence of four GR isoforms in the placenta: GRa, GRb,
GRg and GR-P, although the latter was only identi-
ﬁable in a subset of placentae.14 The most predomi-
nant mature isoform expressed was GRa, consistent
with its ubiquitous expression throughout the body.
This isoform mediates the functional biological
effects of glucocorticoids, including cell growth,
proliferation and differentiation (for a review, see
Pujols et al15), and our studies have indicated that its
expression in the placenta becomes inhibited
following in vitro glucocorticoid exposure.14 The
actions of other GR isoforms also determine func-
tional responses to glucocorticoids: GRb is a domi-
nant inhibitor ofGRa binding,16GR-PenhancesGRa
transcription17 and GRg plays a role in mediating
glucocorticoid resistance in childhood acute
lymphoblastic leukaemia.18
The placental response to glucocorticoids appears
crucial in determining fetal growth outcomes.
Exposure to synthetic glucocorticoids during
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pregnancy is associated with reductions in birth weight in a
number of animalmodels,19e22which often appear sex speciﬁc23 24;
however, data from comparable human studies remain
inconclusive.25e27 Functional responses to glucocorticoids are
determined in part by the relative expression of the different GR
isoforms,which are altered through exposure to glucocorticoids.28
This is an important consideration in the study of placental GR
regulation in pregnant women with asthma, as circulating
endogenous cortisol increases with asthma severity29 and asthma
is often managed with inhaled or oral steroids. This study will
therefore assess the effects of endogenous cortisol and ICS on in
vivoGRexpression in the delivered placenta and its relationship to
birth weight. The aims of this study were (1) to identify whether
maternal asthma was associated with differences in transcription
and translation of placental GR mRNA and GR protein expres-
sion; (2) to identify whether ICS treatment affects regulation of
the placental GR; and (3) to identify sex-speciﬁc relationships
between birth weight centiles and GR protein expression in
asthmatic and control pregnancies.
METHODS
Participants
Ethics approval was gained from the Hunter New England
Health and the University of Newcastle Human Research Ethics
Committees. We have previously reported maternal and fetal
characteristics of a cohort of pregnant women recruited into our
asthma studies9 12 30 and have reported an adherence rate to ICS
treatment of 80%.31 The current data correspond to a subset of
this cohort, where we were able to collect placenta and venous
cord blood with 45 min of delivery. Power analyses were
conducted using Power and Precision Software, ensuring a power
of 80% and a of 0.05, based on variability observed in our
previous ﬁndings.14 Control women without asthma (n¼51)
and women with asthma (n¼123) were recruited at their ﬁrst
antenatal visit to the John Hunter Hospital (Newcastle, NSW,
Australia). Asthma severity was assessed as described previ-
ously,31 and graded as mild, moderate or severe at 12, 18 and
30 weeks gestation.31 Participants were grouped according to the
most severe grade of asthma experienced during pregnancy, as
previously reported.32 33
Given that cigarette smoking can affect birth weight and
attenuate cortisol levels,34 participant self-report of cigarette
smoking was recorded from antenatal records and following
interview at recruitment. Birth weight and length were recorded
and converted into centiles using growth charts35 and a birth
centile calculator (http://www.gestation.net/; Perinatal Insti-
tute, UK), with birth centiles <10 deﬁned as small for
gestational age (SGA).
Placental tissue preparation, RNA isolation and real-time
reverse transcriptionePCR (RTePCR) analysis
Placental tissue samples were pooled from six cotyledons,
blotted to remove blood, snap-frozen and stored at 808C.
Pooling of tissue removes variability across sites on the placenta.
Total RNA was extracted from 0.2 g of crushed frozen placenta
using the TRIzol method (Invitrogen, Mt Waverley, Australia),
as described previously.14 Quantitative real-time RTePCR was
used to determine mRNA abundance of total GR, GRa, GR exon
1A3 and GR heterogeneous nuclear RNA (hnRNA) in placental
samples compared with levels of the housekeeping gene, b-actin.
GR hnRNA is the precursor of GR mRNA and thus serves as
a reliable surrogate marker of gene activity in both fresh tissue
and cultured cells.36 37 The real-time RTePCR protocol, primer
sequences and optimal concentrations were identical to those
reported previously.14 All samples were assayed in triplicate and
variability in mRNA expression was <5%.
Protein extraction and western blot analysis
Placental tissue was homogenised and protein extracted as
described previously.12 Extracted protein samples were prepared
by combining extract (20 mg) with 5 ml of NuPAGE lithium
dodecyl sulfate (LDS) sample buffer. Samples were heated for
12 min at 708C and 2 ml of NuPAGE reducing agent (Invitrogen,
Life Technologies, Carlsbad, California, USA) was added. Protein
samples (20 mg/lane) were separated by electrophoresis through
7% Tris-acetate precast gels on an Xcell SureLock Electrophoresis
cell (Invitrogen). Gels were run at 150 V for 1 h in a Tris-acetate
running buffer with 500 ml of NuPAGE antioxidant (Invitrogen)
in the inner chamber. Proteins were electrophoretically trans-
ferred to 0.45 mm pore nitrocellulose membranes (Hybond-C
Extra, Amersham Biosciences, UK) at 30 V for 1 h. Transfer
membranes were incubated overnight with 5% skim milk in
blocking solution (Tris-buffered saline (TBS) with 5% skim milk
powder). Blots were incubated for 2 h at room temperature with
1:200 dilution of the primary antibody in blocking solution. For
detection of GRa protein, an afﬁnity-puriﬁed rabbit polyclonal
immunoglobulin G (IgG) antibody was used (Santa Cruz
Biotechnology, Santa Cruz, California, USA). Blots were incu-
bated for 1 h at room temperature with a horseradish peroxi-
dase-labelled goat antirabbit secondary antibody provided with
the ECL kit (Pierce Biotechnology, Rockford, Illinois, USA).
Signal detection of antibody complexes was performed using
Pierce Supersignal Dura Extended Duration Substrate (Pierce
Biotechnology) as per the manufacturer ’s instructions. Densi-
tometric analysis (Multi Gauge V2.4) was used to quantify the
intensity of the protein signals relative to a 38 kDa band to
which the secondary antibody bound, to adjust for loading
(ﬁgure 1). We identiﬁed that the 38 kDa band changed with



















Figure 1 Representative western blot of placental protein samples,
indicating the 95 kDa band corresponding to glucorticoid receptor
a (GRa) and the position of the 38 kDa reference band. Lane 1 is the
molecular weight marker; lanes 2e13 are placental protein samples in
duplicate (lanes 2e5, 8 and 9 are placentae samples from controls;
lanes 6, 7, 10e13 are placentae samples from women with mild
asthma; lane 14 is a positive control (pooled placental sample); lane 15
is a positive control (rat brain).
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previously used this method as a control for loading variations.9
Each blot contained a positive control (rat brain protein extract)
and an interassay control (pooled placental sample).
Plasma collection and cortisol radioimmunoassay (RIA)
Plasma was separated from cord blood via centrifugation.
Cortisol concentrations were determined in duplicate in plasma
collected from the placental umbilical vein, using a commercial
RIA kit (Diagnostic Systems Laboratories, Webster, Texas, USA)
following the manufacturer ’s instructions. The detection limit
was 4.7 nmol/l; the intra-assay variation was 5.1% and cross-
reactivity of cortisol antiserum with other steroids was <0.1%.
Statistical analysis
Statistics were performed using the Statistical Package for the
Social Sciences (SPSS v 17; SPSS, Chicage, Illinois, USA). An
a priori decision was made to analyse the data separately by sex
when comparing the effects of asthma severity and treatment,
as past research indicates that placental cortisol metabolism
differs between males and females in the presences of asthma.8 12
The abundance of GR hnRNA and mRNA transcripts was log
(natural) transformed to normalise the data. To assess the effect
of asthma severity and asthma treatment on protein and mRNA
expression abundance, one-way analysis of variance (ANOVA)
was used with Tukey post hoc testing where indicated. Student
t tests and ManneWhitney U tests were used for comparisons
made between two normally and non-normally distributed
variables, respectively. Pearson correlations were performed to
assess associations between the log-transformed expression data,
birth weight centiles and cortisol concentrations. Frequencies of
maternal smoking and SGA births in the control and asthma
groups were analysed using c2. p Values #0.05 were considered
statistically signiﬁcant.
RESULTS
Maternal and neonatal characteristics
The maternal and neonatal characteristics are reported according
to both asthma severity and asthma treatment in tables 1 and 2,
respectively. Maternal age was signiﬁcantly higher in the control
population than both the populations with asthma (F(2,171)¼
8.715, p<0.001). Maternal forced expiratory volume in 1 s
(FEV1) was signiﬁcantly lower in the moderateesevere asthma
group compared with the control and mild asthma groups (F
(2,171)¼3.225, p¼0.043), but did not differ according to asthma
treatment (p¼0.100). More women with asthma smoked
(33.8%) compared with controls (5.9%; c2¼13.364, p¼0.001).
Male birth weight centiles were signiﬁcantly greater than
those of females (t(173)¼2.78, p¼0.006). Female birth weight,
birth weight centile, length, and abdominal and head circum-
ferences were not different between the groups. In females, cord
blood cortisol was signiﬁcantly increased in the moder-
ateesevere asthma group compared with the controls and the
mild asthma groups (F(2,67)¼3.2, p¼0.047), and negatively
correlated with birth weight centiles (r¼e0.286, p¼0.017,
n¼69). Signiﬁcantly more females were born SGA in the group
with moderateesevere asthma (22.5%) than in both the control
(9.5%) and the mild asthma (3.2%) groups (c2¼6.018, p¼0.049).
In male neonates, no difference was observed in birth weight
centiles or cortisol between the control and asthma treatment
groups, and the two were not correlated. Frequency rates of male
infants born SGA did not differ between the control and asthma
groups. Length centiles were signiﬁcantly reduced in the
moderateesevere asthma group compared with the control and
mild asthma groups (F(2,54)¼4.159, p¼0.021).
The effect of asthma on placental GR gene activity, mRNA
expression and protein levels
Placental GR gene activity (as measured through hnRNA
expression) was signiﬁcantly increased in the group with mild
asthma compared with both the moderateesevere asthma group
and the controls (F(2,113)¼2.91, p¼0.049; ﬁgure 2). Total GR
and GRa mRNA were unaffected by asthma, regardless of
severity (ﬁgure 2).
Expression of GR hnRNA was correlated with cord blood
cortisol in the control (r¼0.458, p¼0.008) and in the moder-
ateesevere asthma groups (r¼0.327, p¼0.030), but not in the
mild group. GR hnRNAwas positively correlated with exon 1A3
in the mild (r¼0.703, p<0.001) and the moderateesevere asthma
group (r¼0.851, p<0.001), but not in the control group. Cord
blood cortisol levels were positively correlated with GRa protein
in the mild asthma group only (r¼0.552, p¼0.012). In both the
control and asthma groups, GRa protein was not correlated
with any GR mRNA transcript or birth weight centiles.
Table 1 Maternal characteristics of the study populations according to asthma treatment and asthma severity
Asthma treatment Asthma severity
Control No treatment Inhaled corticosteroids p Value Mild Moderateesevere p Value
n 51 52 71 58 65
Age 29.8 (27.4 to 30.9)* 25.7 (23 to 27) 26.7 (25 to 28) <0.001 26.0 (23.4 to 26.8) 26.5 (25.0 to 28.0) <0.001
Height (cm) 164.2 (162.2 to 165.9) 164.1 (161.8 to 166.1) 164.0 (162.7 to 165.8) 0.99 163.4 (162.0 to 166.0) 164.4 (162.6 to 165.8) 0.81
Weight (early) (kg) 73.9 (65.0 to 77.4) 76.9 (69.2 to 81.1 75.3 (69.8 to 81.3) 0.80 77.4 (68.9 to 80.7) 74.7 (70.0 to 81.6) 0.67
Weight (late) (kg) 83.0 (76.6 to 87.9) 88.3 (81.7 to 92.9 85.4 (80.5 to 91.2) 0.47 88.1 (82.2 to 92.8) 85.3 (80.2 to 91.2) 0.47
BMI 27.4 (24 to 29) 28.3 (26 to 30) 27.7 (26 to 30) 0.82 28.3 (25 to 30) 27.7 (26 to 30) 0.82
Gravida (median, range) 2 (1e10) 2 (1e8) 2 (1e8) 0.11 2 (1e8) 2 (1e8) 0.020
Parity (median, range) 1 (0e6)* 0 (0e4) 1 (0e6) 0.011 0 (0e4) 1 (0e6) 0.004
FEV1 3.2 (3.0 to 3.4) 3.2 (3.0 to 3.3) 3.0 (2.9 to 3.2) 0.10 3.2 (3.0 to 3.4) 3.0 (2.8 to 3.2)y 0.043
Vital capacity 3.9 (3.8 to 4.1) 3.8 (3.6 to 4.0) 3.8 (3.6 to 3.9) 0.70 3.8 (3.6 to 3.9) 3.8 (3.6 to 3.9) 0.71
GC dose, third trimester 0 0 1054.2 (890.7 to 1233.2)z <0.001 234.5 (123.8 to 350.3)x 928.0 (705.9 to 1117.5)z <0.001
Smoking n (%) 3 (5.9%) 14 (26.9%) 20 (28.2%) 0.006 12 (20.7%)x 22 (33.8%)x 0.001
Significance values represent a comparison of each asthma treatment and the control group and of each asthma severity and the control group. Data represent mean (95% CI) unless indicated.
*Significantly higher than the asthma groups.
ySignificantly lower than the mild group.
zSignificantly higher than the control and no treatment groups.
xSignificantly higher than the control group.
BMI, body mass index; FEV1, forced expiratory volume in 1 s; GC, glucocorticoid.
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The effect of glucocorticoid treatment on GR gene activity,
mRNA expression and protein levels
The treatment of asthma varied according to asthma severity
(c2¼26.73, df¼1, p<0.001), with ICS treatment used by 33%
(n¼19) of the group with mild asthma and 79% (n¼52) of the
group with moderateesevere asthma, while the remainder did
not treat their asthma with ICS during pregnancy. The use of
ICS did not affect the already heightened GR hnRNA expression
in the mild asthma group. However, within the moder-
ateesevere asthma group, ICS was associated with signiﬁcantly
lower hnRNA expression compared with the no-treatment
group (t(45)¼2.08, p¼0.050), but hnRNA levels comparable
with the controls (ﬁgure 3). ICS was not associated with
changes to GR total mRNA, GRa mRNA expression or GRa
protein levels (ﬁgure 3).
In the ICS group, both cord blood cortisol and GR hnRNAwere
positively associatedwith exon1A3 expression (r¼0.362, p¼0.011
and r¼0.816, p<0.001, respectively). In this group, the dose of ICS
used in the third trimester was negatively correlated with GR
hnRNA expression (r¼0.378, p<0.001). In the no-treatment
group, no associations were observed between cortisol and
hnRNA or exon 1A3 expression. Further, the expression of total
Table 2 Characteristics of female and male neonates in each study population according to asthma treatment and asthma severity
Control

















0.34 3483.4 (3321.0) 3262.6 (3079.5 to
3445.8)
0.90
BW centile 47.6 (33.0 to 58.2) 54.5 (40.7 to 62.3) 46.4 (37.2 to 55.6) 0.25 50.2 (44.7 to 64.1) 46.3 (34.7 to 54.1 0.85
Length (cm) 51.4 (49.0 to 54.2) 50.9 (49.8 to 52.7) 50.7 (49.4 to 51.7) 0.76 51.4 (50.2 to 52.7) 50.3 (49.1 to 51.5) 0.25
Length centile 70.2 (51.1 to 100.0) 65.2 (54.9 to 84.6) 63.3 (50.5 to 72.0) 0.76 71.0 (59.1 to 82.8) 59.6 (48.4 to 70.8) 0.18
Head circumference (cm) 34.6 (33.3 to 36.9) 34.2 (33.2 to 35.3) 34.5 (34.0 to 34.9) 0.79 34.3 (33.7 to 35.2) 34.3 (34.0 to 34.9) 0.74
Abdominal circumference (mm) 271.6 (238.4 to 304.8) 245.08 (229.0 to 261.2) 264.2 (256.0 to 272.4) 0.37 247.1 (230.6 to 263.6) 264.0 (256.5 to 271.5) 0.37
Cord blood cortisol (mmol/l) 202.72 (162.7 to 238.4) 209.0 (171.4 to 246.5) 254.12 (217.2 to 303.2)* 0.030y 269.61 (194.7 to 294.7) 240.71 (195.6 to 270.9) 0.31
Apgar 5 9.3 (8.9 to 9.6) 9.1 (8.8 to 9.4) 9.3 (9.1e9.4) 0.60 9.2 (8.9 to 9.4) 9.3 (8.9 to 9.4) 0.82
SGA n (%) 2 (9.5) 1 (3.2) 9 (22.5)* 0.049y 3 (9.7) 7 (17.5) 0.54
Males











BW centile 61.9 (50.1 to 72.4) 64.2 (50.0 to 75.6) 55.3 (45.4 to 65.2) 0.31 61.8 (53.2e75.2) 56.4 (41.6 to 63.5) 0.72
Length (cm) 52.3 (50.7 to 53.7) 53.2 (52.9 to 54.9) 51.3 (50.0 to 52.5)* 0.03813,y 53.5 (52.0 to 55.0) 51.9 (50.7 to 53.1) 0.49
Length centile 83.1 (70.3 to 93.7) 94.5 (90.8 to 98.2) 68.5 (55.9 to 82.4)* 0.015y 92.0 (85.4 to 98.5) 75.2 (62.6 to 86.3) 0.36
Head circumference (cm) 34.1 (33.3 to 35.2) 35.3 (34.6 to 36.4) 34.9 (34.1 to 35.7) 0.86 35.2 (33.9 to 36.1) 35.3 (34.5 to 35.9) 0.90
Abdominal circumference (mm) 261.6 (256.1 to 267.1) 264.1 (255.7 to 282.5) 272.6 (263.6 to 281.6) 0.16 264.1 (256.3 to 272.0) 271.1 (262.9 to 279.2) 0.21
Cord blood cortisol (mmol/l) 205.45 (170.4 to 241.2) 233.4 (168 to 298.1) 225.05 (164 to 287.0) 0.45 285.74 (154.7 to 302.3) 251.86 (174.5 to 285.9) 0.42
Apgar 5 9.5 (9.2 to 9.9) 9.1 (8.9 to 9.4) 9.1 (8.8 to 9.5) 0.17 9.2 (9 to 9.5) 9.1 (8.8 to 9.4) 0.11
SGA n (%) 2 (6.6) 1 (3.7) 2 (7.7) 0.82 1 (4.5) 2 (6.5) 0.94
Reported p values represent significance level of univariate analysis of variance of asthma severity or asthma treatment group compared with the control group. Data represent mean (95% CI).
*Significant compared with both the control and mild asthma groups (p<0.05).
ySignificant main effect of asthma severity.
BW, birth weight; SGA, small for gestational age.
Figure 2 The effect of asthma
severity on the relative expression of
glucorticoid receptor (GR)
heterogeneous nuclear RNA (hnRNA),
GR exon 1A3 mRNA, GRa mRNA, total
GR mRNA and GRa protein, compared
with b-actin. Values represent the mean
(6SEM) of natural logarithmic
transformed data. Mod-Sev,
moderatesevere asthma; *p¼0.019
compared with control and
moderateesevere asthma groups.
hnRNA and mRNA analysis: control
n¼33; mild n¼36; and
moderateesevere n¼47. GRa protein
levels: control n¼17; mild n¼18; and
moderateesevere n¼20.
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GR mRNA, GRa mRNA and GRa protein levels did not differ
between the ICS and no-treatment groups. The dose of ICS used
in the third trimester did not correlate with cortisol, GRamRNA
expression, GRa protein levels or birth weight centiles.
The effect of fetal sex on GR gene activity, mRNA expression
and protein levels
Expression levels of total GR mRNA and GRa mRNA in control
and asthmatic pregnancies differed according to fetal sex. In
females, a signiﬁcantly higher abundance of total GR mRNA
was demonstrated in placentae from the control compared with
the asthmatic groups irrespective of asthma severity (F(1,54)¼
4.99, p¼0.003). A similar pattern of abundance was observed
with GRa mRNA in the placentae from females; however, this
failed to reach statistical signiﬁcance (p¼0.08) (ﬁgure 4). In
males, the expression of the total placental GR mRNA and GRa
mRNA transcripts was unchanged with asthma. Protein levels of
GRawere signiﬁcantly higher in placentae from males compared
with females (t(54)¼2.385, p¼0.022; ﬁgure 4), but did not
change with asthma. Placental GR hnRNA and GR 1A3
expression were not independently affected by fetal sex.
The associations between placental expression of hnRNA, 1A3
and cortisol thatwere observedwith ICSwere demonstrated to be
sex speciﬁc. In placentae from males, hnRNA expression was
positively correlated with cortisol in both the control and ICS
groups (r¼0.594, p¼0.005 and r¼0.474, p¼0.003, respectively)
but not the no-treatment group. Expression of exon 1A3 was also
correlated with cortisol in the ICS group (r¼0.630, p¼0.002).
Expression of both hnRNA and exon 1A3, however, was unaf-
fected by the dose of ICS used in the third trimester. In placentae
from females, no correlation was observed between hnRNA
expression, exon 1A3 and cortisol in any group. However, third
Figure 3 The effect of inhaled
corticosteroid (ICS) treatment on
glucorticoid receptor (GR)
heterogeneous nuclear RNA (hnRNA)
expression (top panel) and GR exon
1A3 expression (bottom panel) in
placentae collected from controls and
women with mild or moderateesevere
asthma. *p¼0.05. Control n¼33, no
treatment; mild n¼22 and
moderateesevere n¼10. ICS, mild
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Figure 4 The effect of fetal sex on
heterogeneous nuclear RNA (hnRNA)
and mRNA expression and protein
levels in placentae from control
pregnancies (open circles) or
pregnancies complicated by mild
asthma (grey circles) or
moderateesevere asthma (black
circle). Circles represent means
(6SEM) of natural logarithmic
transformed expression levels
compared with b-actin. #p¼0.003
compared with controls; *p¼0.02
compared with males. mRNA analysis:
female, control n¼11, mild n¼16,
moderateesevere n¼29; male, control
n¼22, mild n¼20, moderateesevere
n¼18. Protein analysis: female, control
n¼8, mild n¼11, moderateesevere
n¼10; male, control n¼9, mild n¼9,
moderateesevere n¼10.
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trimester dose of ICS was negatively associated with hnRNA and
exon 1A3 expression (r¼0.523, p¼0.004 and r¼0.415,
p¼0.028, respectively).
The effect of cigarette smoking on placental GR gene activity,
mRNA expression and protein levels
Smoking was associated with a signiﬁcant decrease in female
birth weight centiles in pregnancies complicated by asthma
(smoker, mean¼29.24, SEM¼6.00; non-smoker, mean¼55.82,
SEM¼3.76; t(69)¼3.808, p<0.001); smoking did not affect male
birth weight centiles. Cigarette smoking was, however, not
associated with changes in GR gene activity, mRNA transcripts
or protein levels in placenta from either male or female births
(data not shown).
DISCUSSION
The ﬁndings of this work indicate sex-speciﬁc alterations to
placental GR regulation, cortisol and growth in the presence of
asthma. Speciﬁcally, female but not male birth weight centiles
were inversely associated with cord blood cortisol levels in the
presence of maternal asthma; however, concurrent changes to
placental GRa protein were not evident. These data suggest that
decreased female fetal growth is not due to an increase in
glucocorticoid sensitivity via increased GRa protein levels per se.
The comparable GRa protein levels observed in placentae from
males and females in both the asthmatic and control groups should
predict equal sensitivity to cortisol and similar downstream func-
tional responses. In the males, this held true, with no differences in
birth weight centiles apparent between the asthmatic or control
groups. However, in the female placentae, GRa protein levels were
not predictive of birth weight outcomes. In females, low birth
weight centiles occurred with the highest cortisol levels that char-
acterised the group with untreated, moderateesevere asthma.
Maternal smoking further reduced female birth weight centiles in
this group, while not affecting placental GRa protein levels. These
ﬁndings suggest a role for an alternative cortisol-mediated pathway
in the regulation of female fetal growth. A likely candidate is the
insulin-like growth factor (IGF) axis, as increased cortisol is associ-
ated with decreased levels of IGF-1 and IGF-binding protein-3
(IGFBP-3) in cases of SGA infants.38 Further, in a study of appro-
priately grown female fetuses in the presence of maternal asthma,
we have recently reported increased cord blood IGF-1 concentra-
tions comparedwith controls,whichwehave suggested contributes
to maintainance of growth in these individuals. In male fetuses, no
differences in IGF-1 concentrations or growth were observed
between the controls and the groups with asthma. Ongoing work
will elucidate whether the IGF axis plays a role in the reductions in
female growth that accompany untreated asthma, which we have
previously documented. Alternatively, a post-translational modiﬁ-
cation to femaleplacentalGRmayoccur,which regulates functional
outcomes to cortisol. This may occur through phosphorylation of
GR protein by p38 mitogen-activated protein kinase (p38MAPK),
which has been observed previously in the placenta.39 GR phos-
phorylation in other tissue results in reduced GR binding afﬁnity40
and increased nuclear factor-kB (NF-kB)-dependent, proin-
ﬂammatory cytokine production (for a review, see Rincon and
Davis41). Altered p38MAPK activity with maternal asthma may
therefore be an important factor contributing to our current ﬁnding
of decreased female fetal growth in a high cortisol environment, as
well as to our previous report of increased placental proin-
ﬂammatory cytokine mRNA expression.33 Whether p38MAPK
activity is altered by asthma or ICS is currently unknown.
Untreated maternal asthma was associated with a high fetal
cortisol environment and increased GR gene activity and exon
1A3 mRNA expression in both male and female placentae. These
ﬁndings suggest that increases in cortisol result in increased GR
gene activity, with preferential usage of the exon 1A3 promoter
region. Gene activity was restored to control levels when ICS
were used to treat asthma. This was particularly evident in
female placentae, where an inverse association was observed
between the dose of ICS and GR gene activity. Together these
data suggest a potential mechanism, in that ICS inhibits
maternal cortisol levels resulting in decreased placental exposure
to maternal cortisol which leads to decreased placental GR gene
transcription. While the mechanisms contributing to increased
GR gene activity and 1A3 promoter usage have not been well
deﬁned, increased GR 1A3 promoter usage in the presence of
cortisol has been reported in leukaemic cell lines.28 The current
study supports these ﬁndings, illustrating that in placental cells,
cortisol is associated with an increase in GR gene activity and
usage of the GR 1A3 promoter.
Glucocorticoid-dependent suppression of GR expression (ie,
homologous downregulation) has been shown to be amechanism
involved in limiting hormone responsiveness.42 43 The absence of
such a mechanism in the male placentae is interesting. It appears
that the male placenta does not respond to the presence of a high
cortisol environment in the archetypical manner, and instead the
placental GR appears cortisol resistant. Consequentially, GRa
protein levels inmales also remained unaltered from control levels
in the presence of asthma, as do the downstream functional
effects typically associated with cortisol binding (such as growth
and placental cytokine inhibition33).
Despite signiﬁcant reductions in GR mRNA in female
placentae in the asthma compared with the control groups, no
change in GRa protein levels were observed. This may be
accounted for by differences in GRa mRNA stability or, alter-
natively, may result from preferential transcription of other GR
isoforms, resulting in differential glucocorticoid sensitivity. We
have previously demonstrated decreased mRNA expression of
two placental GR isoforms, GRa and GR-P, following in vitro
treatment of placentae with the synthetic glucocorticoid dexa-
methasone, while GRb was unaltered.14 Given that the GR-P
isoform appears to be involved in upregulating GRa activity,17
decreased GR-P expression in the presence of asthma-induced
increases in cortisol may result in reduced placental glucocorti-
coid sensitivity. The evidence for glucocorticoid-speciﬁc effects
on GR isoform-speciﬁc transcription is conﬂicting and appears to
be tissue speciﬁc. An increased ratio of GRa to GRb protein has
been demonstrated in dexamethasone-treated nasal polyp tissue
in vitro,44 while decreased ratios are observed following gluco-
corticoid exposure of bronchial epithelial cells.45 46 Further,
increased GRb to GRa protein ratios have been demonstrated in
cases of glucocorticoid insensitivity in a range of inﬂammatory
conditions (asthma, nasal polyps and ulcerative colitis).47e49 The
sex from which the donor tissue was derived was not included in
these studies, but may in part explain the varied results.
The present study has provided insight into sex-speciﬁc
regulation of the GR in placentae of pregnancies complicated
by asthma, characterised by increased endogenous cortisol and
the use of exogenous glucocorticoids. This provides a platform
to examine further the regulation of placental GR and its
downstream effects on cortisol signalling, and may further
elucidate determinants of glucocorticoid sensitivity, contrib-
uting to our understanding of sex-speciﬁc differences in fetal
growth in utero. Scientiﬁcally, these ﬁndings necessitate that
any further studies addressing tissue responses to corticoste-
roids should take into consideration the sex from which the
tissue was derived in interpretation of the results. Clinically,
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the ﬁndings of this work indicate that male and female growth
responses to maternal pathology and/or corticosteroid exposure
are sex speciﬁc. This in itself warrants further study, as it may
have important implications for the clinical management of
observed fetal growth alterations in pregnancies complicated by
asthma.
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